Emergent BioSolutions Inc. (EBS)
Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2025 Earnings Call May 7, 2025 5:00 PM ET Company Participants Frank Vargo - Vice President, Assistant Treasurer Joe Papa - President and Chief Executive Officer Rich Lindahl - Executive Vice President and Chief Financial Officer Conference Call Participants Jessica Fye - JPMorgan Yi Chen - H.C. Wainwright Operator Good day and thank you for standing by.
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.59 per share a year ago.
Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript
Emergent BioSolutions Inc. (NYSE:EBS ) Q4 2024 Earnings Conference Call March 3, 2025 6:00 AM ET Company Participants Frank Vargo - Assistant Treasurer Joseph Papa - President and Chief Executive Officer Richard Lindahl - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Nick Richitt - JPMorgan Brandon Folkes - Rodman & Renshaw Operator Good day, and thank you for standing by. Welcome to Emergent BioSolutions Inc. Fourth Quarter 2024 Earnings Conference Call.
Emergent Biosolutions (EBS) Q4 Earnings Top Estimates
Emergent Biosolutions (EBS) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.35 per share. This compares to loss of $0.77 per share a year ago.
Emergent BioSolutions: Stock Is A Likely Winner In 2025
Emergent BioSolutions has a sound turnaround strategy in place that is producing positive results. Emergent BioSolutions' cost-cutting efforts have the company on track for profitability in 2025. The undervaluation leaves plenty of room for the upside for the stock.
Why Emergent BioSolutions Stock Blasted Higher Today
An analyst initiated coverage of Emergent BioSolutions (EBS 11.85%) stock as the last trading week of 2024 kicked off, and investors reacted quite positively to the move. On the news, they piled into the stock, ultimately sending it to a nearly 12% gain on the day.
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.
Why Emergent BioSciences Stock Plummeted Today
Emergent BioSolutions (EBS -5.59%) saw its shares tumble on Tuesday, due to news of a share sell-off. The vaccine maker divulged in a regulatory filing that several institutional share and warrant holders are selling such securities.
Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic
Emergent BioSolutions' Q3 earnings report led to a 20% surge in its share price, now valued at ~$11 per share. The company's market cap is approximately $595 million, reflecting investor confidence post-earnings announcement. Emergent focuses on innovative preparedness and response solutions for various public health threats.
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024
On Thursday, Emergent BioSolutions Inc. EBS stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.
New Strong Buy Stocks for November 7th
MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024.
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript
